Medicine & Life Sciences
Neoplasms
100%
ARRY-470
52%
Pharmacokinetics
46%
veliparib
44%
Drug Development
41%
Poly(ADP-ribose) Polymerase Inhibitors
37%
Clinical Trials
33%
tropomyosin kinase
32%
Maximum Tolerated Dose
30%
Therapeutics
28%
Lymphoma
25%
Biomarkers
25%
Colorectal Neoplasms
23%
Tetrahydrouridine
23%
National Cancer Institute (U.S.)
21%
5-fluoro-2'-deoxycytidine
21%
Circulating Neoplastic Cells
21%
Sorafenib
20%
Sarcoma
20%
NSC 724998
19%
Biopsy
18%
Safety
18%
Pharmaceutical Preparations
18%
HSP90 Heat-Shock Proteins
17%
cediranib
17%
Aggressive Fibromatosis
17%
Progression-Free Survival
16%
Topotecan
16%
Poly(ADP-ribose) Polymerases
16%
belinostat
16%
Histone Deacetylase Inhibitors
16%
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
16%
DNA Damage
16%
Alveolar Soft Part Sarcoma
15%
Hypoxia-Inducible Factor 1
15%
Adenocarcinoma
15%
Investigational Drugs
14%
Drug Therapy
13%
MK-1775
13%
Liver
13%
Non-Small Cell Lung Carcinoma
12%
Deoxycytidine
12%
Appointments and Schedules
12%
Amyloid Precursor Protein Secretases
11%
United States Food and Drug Administration
11%
Antineoplastic Agents
11%
pazopanib
11%
TimeLine
10%
4-hydroxy-N-desmethyltamoxifen
10%
Mutation
10%